MA56341B1 - Combinaison d'ibuprofène et de tramadol pour soulager la douleur - Google Patents

Combinaison d'ibuprofène et de tramadol pour soulager la douleur

Info

Publication number
MA56341B1
MA56341B1 MA56341A MA56341A MA56341B1 MA 56341 B1 MA56341 B1 MA 56341B1 MA 56341 A MA56341 A MA 56341A MA 56341 A MA56341 A MA 56341A MA 56341 B1 MA56341 B1 MA 56341B1
Authority
MA
Morocco
Prior art keywords
tramadol
combination
ibuprofen
pain relief
dosage
Prior art date
Application number
MA56341A
Other languages
English (en)
French (fr)
Inventor
De La Torre Marta Vicario
Alonso Fernando García
Menéndez Nuria Sanz
Pérez Antonio Portolés
Serna Luis Narciso Santé
Butrón María Del Rosario Salas
Castrillón Emilio Vargas
Pérez Carlos Calandria
Córdoba Raquel Horcajada
Ruiz Ángel José Muñoz
Calvo Antonia Gómez
García Jose Angel Sánchez
Gonzalez Ester Duart
Original Assignee
Farmalider Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider Sa filed Critical Farmalider Sa
Publication of MA56341B1 publication Critical patent/MA56341B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
MA56341A 2019-07-09 2020-07-08 Combinaison d'ibuprofène et de tramadol pour soulager la douleur MA56341B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382583 2019-07-09
PCT/EP2020/069306 WO2021005129A1 (en) 2019-07-09 2020-07-08 Combination of ibuprofen and tramadol for relieving pain

Publications (1)

Publication Number Publication Date
MA56341B1 true MA56341B1 (fr) 2023-07-31

Family

ID=67480112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56341A MA56341B1 (fr) 2019-07-09 2020-07-08 Combinaison d'ibuprofène et de tramadol pour soulager la douleur

Country Status (21)

Country Link
US (1) US12514833B2 (https=)
EP (1) EP3996699B1 (https=)
JP (1) JP7656339B2 (https=)
CN (1) CN114080221B (https=)
AU (1) AU2020309160B2 (https=)
BR (1) BR112022000242A2 (https=)
CA (1) CA3145632C (https=)
DK (1) DK3996699T3 (https=)
ES (1) ES2952013T3 (https=)
FI (1) FI3996699T3 (https=)
HR (1) HRP20230677T1 (https=)
HU (1) HUE062529T2 (https=)
MA (1) MA56341B1 (https=)
MD (1) MD3996699T2 (https=)
MX (1) MX2022000373A (https=)
MY (1) MY207573A (https=)
PL (1) PL3996699T3 (https=)
PT (1) PT3996699T (https=)
RS (1) RS64500B1 (https=)
SI (1) SI3996699T1 (https=)
WO (1) WO2021005129A1 (https=)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
IT1264857B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
WO2000025769A1 (en) 1998-11-02 2000-05-11 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US6251945B1 (en) 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
US6211246B1 (en) 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6342530B1 (en) 2000-11-14 2002-01-29 Farmacon-Il, Llc Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt
US6727286B2 (en) 2001-11-02 2004-04-27 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
JP5185488B2 (ja) 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ，インコーポレーテッド ２−（４−イソブチルフェニル）プロピオン酸の医薬組成物
ES2287519T3 (es) 2002-10-25 2007-12-16 Dompe S.P.A. Composiciones inyectables indoloras que contienen sal de acidos 2-arilpropionicos.
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
EP2149546A1 (en) * 2008-07-31 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Salts of tramadol and ibuprofen and their crystal form in the treatment of pain
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
AU2010224063B2 (en) 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
US8735452B2 (en) 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
ES2356762B1 (es) * 2009-09-04 2011-11-24 Farmalider S.A. Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma.
MX2010004974A (es) 2010-05-04 2011-11-23 Senosiain S A De C V Lab Combinacion de un aine y un aminoacido.
CA2833307C (en) 2011-04-12 2018-01-23 Revogenex Inc. Intravenous administration of tramadol
ES2552521T3 (es) 2012-02-20 2015-11-30 Pharmaceutical Solutions Industry Ltd Infusión intravenosa de ibuprofeno
ES2423866B1 (es) 2012-02-22 2014-06-10 Farmalider, S.A. Composición farmaceútica de ibuprofeno y tramadol para inyección
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
US20150290211A1 (en) * 2014-04-10 2015-10-15 Locl Pharma, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
EP3996699A1 (en) 2022-05-18
EP3996699B1 (en) 2023-06-28
SI3996699T1 (sl) 2023-10-30
AU2020309160B2 (en) 2025-06-26
WO2021005129A1 (en) 2021-01-14
PT3996699T (pt) 2023-07-27
HUE062529T2 (hu) 2023-11-28
CN114080221A (zh) 2022-02-22
US12514833B2 (en) 2026-01-06
DK3996699T3 (da) 2023-07-24
BR112022000242A2 (pt) 2022-05-31
CA3145632C (en) 2024-03-12
RS64500B1 (sr) 2023-09-29
MY207573A (en) 2025-03-05
HRP20230677T1 (hr) 2023-10-13
MX2022000373A (es) 2022-02-10
PL3996699T3 (pl) 2023-10-30
JP7656339B2 (ja) 2025-04-03
AU2020309160A1 (en) 2022-02-17
FI3996699T3 (fi) 2023-08-01
CA3145632A1 (en) 2021-01-14
JP2022540854A (ja) 2022-09-20
CN114080221B (zh) 2023-12-05
MD3996699T2 (ro) 2023-11-30
ES2952013T3 (es) 2023-10-26
US20220249414A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
MA48051B1 (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
EA200101026A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
MA69295B1 (fr) Dose de départ de conjugués de pth
MA29871B1 (fr) Composition pharmaceutique concue pour ameliorer la fonction cognitive
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MA45972B1 (fr) Unité posologique orodispersible contenant un composant d'estétrol
MA52861B1 (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
MA56341B1 (fr) Combinaison d'ibuprofène et de tramadol pour soulager la douleur
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA62176A1 (fr) Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène
BG105434A (bg) Сертралинов орален концентрат
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete